Phaseolean®: Carb control & satiety signalling to target body’s GLP-1, PYY & Ghrelin levels
New clinical studies showcase Phaseolean®’s effects on endogenous GLP-1, PYY and Ghrelin, adding to the established science of α-amylase inhibition, postprandial glycemic control and weight management